Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
Go or no go? Vaccines and neurology up for discussion
EP Vantage
Tue, 02/28/23 - 11:05 am
FDA
Acadia Pharmaceuticals
Apellis Pharmaceuticals
AstraZeneca
Biogen
Biomarin
Cidara Therapeutics
Emergent BioSolutions
GSK
Incyte
Ionis Pharmaceuticals
Melinta Therapeutics
Mundipharma
Novartis
Pfizer
Pharming
Regeneron
Roche
vaccines
RSV
ALS
COVID-19
Billy Dunn, FDA’s top neuroscience official to depart agency
RAPS.org
Mon, 02/27/23 - 07:12 pm
Billy Dunn
FDA
Neurosciences
Biogen
Aduhelm
Medicare maintains limits on Eisai’s new Alzheimer’s drug
BioPharma Dive
Thu, 02/23/23 - 04:27 pm
Medicare
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Biogen CEO says company 'lost its way,' cuts $125M MS partnership amid declining revenue
Endpoints
Wed, 02/15/23 - 06:30 pm
Biogen
InnoCare Pharma
orelabrutinib
earnings
Biogen chairman to step down as new CEO walks thin line with Alzheimer's launch Leqembi
Fierce Pharma
Wed, 02/15/23 - 06:28 pm
Biogen
Chris Viehbacher
Stelios Papadopoulos
Pharma CEOs
Alzheimer's disease
Leqembi
FDA adds warning of 'larger areas of bleeding' in brain to Biogen's Aduhelm label
Endpoints
Tue, 02/14/23 - 11:01 am
Biogen
Aduhelm
FDA
Alzheimer's disease
Biogen, Sage Get FDA Priority Review of Zuranolone
Marketwatch
Mon, 02/6/23 - 10:47 am
Biogen
SAGE Therapeutics
FDA
zuranolone
priority review
postpartum depression
major depressive disorder
Biogen/ Ionis ALS therapy set for March FDA AdCom meeting
Seeking Alpha
Mon, 01/23/23 - 11:12 am
Biogen
Ionis Pharmaceuticals
FDA
ALS
tofersen
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
Motley Fool
Thu, 01/19/23 - 10:15 am
Biogen
Eisai
Alzheimer's disease
Leqembi
lecanemab
New Biogen CEO tips subcutaneous lecanemab to help expansion into pre-symptomatic Alzheimer’s
Fierce Pharma
Fri, 01/13/23 - 10:59 am
Biogen
Chris Viehbacher
lecanemab
Alzheimer's disease
Pharma CEOs
Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?
Clinical Trials Arena
Fri, 01/13/23 - 10:49 am
clinical trials
Alzheimer's disease
Eisai
Biogen
Eli Lilly
Leqembi
lecanemab
donanemab
After FDA nod, Eisai and Biogen file lecanemab in EU
Pharmaphorum
Wed, 01/11/23 - 11:04 pm
Eisai
Biogen
lecanemab
Europe
Alzheimer's disease
Lilly, Biogen and more gear up for blockbuster launches in 2023: report
Fierce Pharma
Wed, 01/11/23 - 11:00 pm
Clarivate
drug launches
Eli Lilly
Biogen
GSK
Bristol Myers Squibb
Biogen, scrapping for SMA market share, bets $10M on implant to improve delivery of Spinraza
Fierce Pharma
Tue, 01/10/23 - 10:55 am
Biogen
Alcyone Therapeutics
SMA
Spinraza
devices
Medtech
Eisai learns from Biogen’s Aduhelm disaster
EP Vantage
Mon, 01/9/23 - 10:35 am
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
drug pricing
Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy
BioPharma Dive
Sun, 01/8/23 - 10:04 pm
Eisai
Biogen
drug pricing
Leqembi
Alzheimer's disease
lecanemab
FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision
BioPharma Dive
Fri, 01/6/23 - 03:40 pm
Eisai
Biogen
lecanemab
Leqembi
Alzheimer's disease
FDA
Biogen and Alcyone Therapeutics partner up on novel device for neurological ASO therapies
Biopharma Reporter
Thu, 01/5/23 - 04:56 pm
devices
Medtech
Biogen
Alcyone Therapeutics
ThecaFlex DRx
ASO therapies
Biogen splits R&D executive role, promoting interim head Singhal
BioPharma Dive
Thu, 01/5/23 - 04:47 pm
Biogen
R&D
Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report
Fierce Pharma
Fri, 12/30/22 - 10:50 am
Biogen
Aduhelm
Alzheimer's disease
FDA
US Congress
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »